MHRA authorises GSK’s Omjjara for treating symptoms in adult myelofibrosis with anaemia

GSK plcâs small molecule Omjjara (momelotinib), was granted marketing authorization (MA) yesterday (January 31) by the Medicines and Healthcare products Regulatory Agency (MHRA).